Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the […]
abbott
MIT study reveals the problem with bioresorbable stents
Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb […]
Judge rips into Abbott’s diabetes test strip supplier over discovery fraud
A supplier that sells an international version of Abbott‘s (NYSE:ABT) FreeStyle Diabetes test strips committed discovery fraud when it forked over only a select group of relevant documents last year, according to a U.S. magistrate judge. Lois Bloom ruled that the supplier, H&H, lost the right to invoke attorney-client privilege when it is deposed about […]
Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018
Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) […]
Abbott, Surmodics ink $25m deal for drug-coated balloon tech
Abbott (NYSE:ABT) is slated to pay $25 million upfront for the global commercialization rights to Surmodics‘ (NSDQ:SRDX) SurVeil drug-coated balloon, the companies announced today. The company’s drug-device combo, which is in pivotal trials in the U.S., is designed to treat peripheral artery disease in the superficial femoral artery. According to the deal, Abbott could also negotiate […]
Abbott’s FreeStyle Libre glucose monitoring app launches in Europe
Abbott (NYSE:ABT) said today that it launched an app for its FreeStyle Libre glucose monitoring system in Europe that can be used with both iPhone and Android smartphones. The mobile app is designed to give people with diabetes direct access to their glucose data on their smartphones. Without the app, FreeStyle Libre users have to carry […]
Dexcom takes on Abbott in head-to-head glucose monitoring trial
Updated to include a statement from Abbott. Dexcom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott‘s (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system. The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by […]
Global sales for Abbott’s diabetes biz jumps 33% in Q4
Worldwide sales for Abbott‘s (NYSE:ABT) diabetes business jumped 33% in the fourth quarter of 2017, the company reported, driven largely by its FreeStyle Libre continuous glucose monitoring system. The device is the only CGM system on the market that is calibrated at the factory and eliminates the need for people with diabetes to perform routine […]
Dexcom posts cautious 2018 forecast despite Street-beating Q4, FY17 prelims
Dexcom (NSDQ:DXCM) shares fell today after the company issued conservative guidance for its expected revenue in 2018. The company also posted Street-beating preliminary results for its fourth quarter and full-year 2017 revenues. The company is facing competition in the new year after the FDA approval of Abbott‘s (NYSE:ABT) continuous glucose monitor, the FreeStyle Libre. But chief executive […]
Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor
Abbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitor is now available to Medicare patients, after the Centers for Medicare & Medicaid Services determined that the device can be classified as a therapeutic CGM. The FreeStyle Libre is designed to read glucose levels through a sensor worn on the back of a person’s upper […]
